Psilocybin Shows Promise in Reducing Symptoms of Body Dysmorphic Disorder
核心洞察
A pilot study indicates that psilocybin significantly reduced symptoms in individuals with body dysmorphic disorder (搜索) (BDD).
Brain scans revealed that psilocybin treatment increased connectivity between brain regions related to emotional processing and cognitive activity.
The improvement in BDD symptoms correlated with the strengthening of connections within brain networks, suggesting enhanced brain flexibility.
A recent study published in Psychedelics suggests that psilocybin, the active compound in "magic" mushrooms, may offer therapeutic benefits for individuals suffering from body dysmorphic disorder (搜索) (BDD). The pilot trial, involving eight participants with treatment-resistant BDD, demonstrated a significant reduction in symptoms following a single 25-milligram dose of psilocybin. BDD is characterized by obsessive preoccupation with perceived physical flaws, often leading to eating disorders (搜索) and other unhealthy behaviors.
Enhanced Brain Connectivity
Brain scans conducted as part of the study revealed that psilocybin treatment led to increased connectivity between various brain regions associated with emotional processing, cognitive activity, and self-perception. Notably, participants who exhibited the greatest strengthening of these neural connections experienced the most substantial improvement in their BDD symptoms within a week of treatment.
Expert Commentary
According to the research team, led by Chen Zhang from the New York State Psychiatric Institute, these findings align with growing evidence that psychedelic compounds like psilocybin can promote mental health by enhancing the brain's capacity for flexibility and integration. "By facilitating communication within and between brain networks that are often dysregulated in psychiatric disorders, psilocybin may help restore more adaptive cognitive and emotional functioning," the team stated in a news release.
Future Directions
While these initial results are promising, the researchers emphasize the need for larger-scale studies to validate the effectiveness of psilocybin in treating BDD and to determine the durability of its effects. Further investigation is also warranted to explore the optimal dosing regimens and to identify potential risks and benefits associated with psilocybin treatment in this patient population.